Please assess the completion status of the following clinical trial:

Trial Title: Premature Ventricular Contractions (PVCs) and Blood Pressure Control

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Frequent symptomatic premature ventricular contractions (PVCs) (\>10% of total QRSs on a 24-hour Holter)~* Willingness to participate in research~Exclusion Criteria:~* Age \> 65 years old~* Pacemaker implantation~* Implantable cardioverter defibrillator implantation requiring pacing~* Sick sinus syndrome~* Atrio-ventricular (AV) block~* Left ventricular dysfunction defined as left ventricular ejection fraction \< 50%~* History of myocardial infarction or coronary artery disease~* Severe left ventricular hypertrophy (wall thickness \> 1.5 cm by echocardiography performed within 3 months from enrollment)~* Severe liver dysfunction~* Creatinine clearance of 35 mL/min/1.73 square meters or less~* Pregnancy~* Known hypersensitivity to the drug~* QRS duration \> 120 ms~* Recent change in blood pressure medication within 30 days of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PVC Suppression then Placebo (Type: PLACEBO_COMPARATOR): This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
- Placebo then PVC Suppression (Type: PLACEBO_COMPARATOR): This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).